Agenda

MONDAY, OCTOBER 16

	8:00 AM–6:00 PM	Poster Presentations
	8:00	Opening Remarks and Welcome Kishor Bhatia, PhD, MRCPath National Cancer Institute, NIH Bethesda, MD, USA
	8:15	P1: Viral Malignancies and an International Perspective John Ziegler, MD, MSc University of California, San Francisco, Comprehensive Cancer Center San Francisco, CA, USA
	9:00 AM–10:00 AM	KSHV and Kaposi's Sarcoma (KS) Moderator: Denise Whitby, PhD
	9:00	P2: Modulation of Cell Signaling and Angiogenesis by KSHV Blossom Damania, PhD University of North Carolina at Chapel Hill Chapel Hill, NC, USA
	9:30	P3: AIDS-Associated Kaposi's Sarcoma (KS) at 25: A Model for the Evaluation of Targeted Antiangiogenesis Therapy Susan Krown, MD Memorial Sloan-Kettering Cancer Center New York, NY, USA
	10:00	Break
	10:20 AM–12:05 PM	Session 1: Kaposi’s Sarcoma–Associated Herpesvirus (KSHV/HHV-8): Pathogenesis of Disease and Pathogenesis-Based Therapy Moderator: Robert Yarchoan, MD and Andrew Grulich, PhD
	10:20	Activation of Kaposi’s Sarcoma–Associated Herpesvirus (KSHV) to Lytic Replication by the Cytotoxic Chemotherapy Drugs Vincristine and Doxorubicin Kazushi Nakano, MD, National Cancer Institute, Bethesda, MD, USA
	10:35	Identification of Novel NFkB Inhibitors in Primary Effusion Lymphoma Cells Ethel Cesarman, MD, PhD, Weill Medical College of Cornell University, New York, NY, USA
	10:50	Rapamycin is Efficacious Against Primary Effusion Lymphoma (PEL) Dirk Dittmer, PhD, University of North Carolina at Chapel Hill, USA
	11:05	Cyclooxygenase-2 (COX-2) Induced by KSHV Early During In Vitro Infection of Target Cells Plays a Role in the Maintenance of Latent Viral Gene Expression Neelam Sharma-Walla, PhD, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
	11:20	Intracellular KSHV Load Determines Early Loss of Immune Synapse Components Laura Adang, PhD, University of Virginia, Charlottesville, VA, USA
	11:35	HHV-8 Infects and Replicates in Primary Cultures of Activated B Lymphocytes Through DC-SIGN Giovanna Rappocciolo, PhD, University of Pittsburgh, PA, USA
	11:50	KSHV-LANA Stabilizes c-Myc by Activating ERK1/2 and Inhibiting GSK-3 Jianyong Liu, MD, PhD, Johns Hopkins School of Medicine, Baltimore, MD, USA
	12:05 PM–1:25 PM	Lunch
	1:25 PM–2:30 PM	Lymphoma and EBV as a Therapeutic Target
	1:25	Introductory Remarks Elliott Kieff, MD, PhD Harvard Medical School Boston, MA, USA
	1:30	P4: InterLymph: An International Collaboration on the Epidemiology of Non-Hodgkin Lymphoma Wendy Cozen, DO, MPH Keck School of Medicine, University of Southern California Los Angeles, CA, USA
	2:00	P5: Pathogenesis of B-Cell Lymphomas: Implications in the Context of AIDS Gianluca Gaidano, MD, PhD Amedeo Avogadro University of Eastern Piedmont Novara, Italy
	2:30 PM–3:15 PM	Session 2: Lymphoma and Epstein-Barr Virus (EBV): New Insights and Treatments Moderator: Kevin Howcroft, PhD, and Sam Mbulaiteye, MD
	2:30	Elevated Activation-Induced Cytidine Deaminase (AID) Expression Preceding the Diagnosis of AIDS-Associated Burkitt's Lymphoma Marta Epeldegui, David Geffen School of Medicine at University of California, Los Angeles, CA, USA
	2:45	Development of a Therapeutic Vaccine for HIV-associated Hodgkin's Lymphoma Rajiv Khanna, PhD, Queensland Institute of Medical Research, Brisbane, Australia
	3:00	EBV Gene Transcription Kinetics During Viral Reactivation by Bortezomib in Cell Lines and in a Clinical Setting Rachel Bagni, MS, NCI-Frederick, Frederick, MD, USA
	3:15	Break
	3:30 PM–4:30 PM	Session 3: Clinical Management of AIDS-Associated Lymphoma Moderator: Alexandra Levine, MD, and Richard Ambinder MD, PhD
	3:30	Randomized Phase II Trial of Infusional EPOCH Chemotherapy Given Either Concurrently with or Sequentially Followed by Rituximab in HIV-Associated Lymphoma: AIDS Malignancy Consortium Trial 034 Joseph Sparano, MD, Montefiore-Einstein Cancer Center, Bronx, NY, USA
	3:45	Abbreviated EPOCH-Rituximab Therapy with HAART Suspension is Highly Effective and Tolerable in AIDS-related Lymphoma Kieron Dunleavy, MD, National Cancer Institute, Bethesda, MD, USA
	4:00	Dose-Modified Oral Chemotherapy for AIDS-related Non-Hodgkin's Lymphoma (AR-NHL) in East Africa: Impact on CD4+ Count and HIV-1 Replication; and Retrospective Look at Similar Regimen in Pre-HAART Era in the USA Walter Mwanda, MBChB, MD, University of Nairobi College of Health Sciences and Kenyatta National Hospital, East Africa-Case Research Collaboration Nairobi, Kenya
	4:15	Discussion
	4:35 PM–6:00 PM	Adjourn to Posters

TUESDAY, OCTOBER 17

	8:00 AM–6:00 PM	Poster Presentations
	8:10	Administrative Remarks Geraldina Dominguez, PhD
	8:15 AM–10:15 AM	HPV, Disease and Vaccine Moderator: Joel Palefsky, MD, FRCP
	8:15	P6: HPV Infection and Cancer in Normal and Immunologically Impaired Hosts Douglas Lowy, MD National Cancer Institute, NIH Bethesda, MD, USA
	8:45	P7: HPV Infection in HIV-Positive Women Silvia Franceschi, MD International Agency for Research on Cancer Lyon, France
	9:15	P8: HPV VLP Vaccine: Clinical Trial Results and Implementation Challenges Diane Harper, MD, MPH, MS Norris Cotton Cancer Center, Dartmouth Medical School Hanover, NH, USA
	9:45	P9: Development of a Broadly Protective HPV Vaccine Based on L2 Richard Roden, PhD Johns Hopkins School of Medicine Baltimore, MD, USA
	10:15	Break
	10:35 AM–12:00 PM	Session 4: Human Papillomavirus (HPV): Diverse Sites of Infection with Implications to Treatment and Prevention Moderator: T-C Wu, MD, PhD, and Elizabeth Read-Connole, PhD
	10:35	Human Papillomavirus (HPV) Infection of the Anus is More Prevalent and Diverse than Cervical HPV Infection Among HIV-Infected Women in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) Erna Kojic, MD, The Miriam Hospital, Providence, RI, USA
	10:50	Six-Month History of Oral Versus Cervical Human Papillomavirus Infection Gypsyamber D'Souza, PhD, Johns Hopkins University, Baltimore MD, USA
	11:05	Clinical Profile of HIV-Positive Women with Cervical Cancer in India Aruna Alahari, MD, Tata Memorial Hospital, Mumbai, India
	11:20	A High Prevalence of High Risk Human Papillomavirus and Cervical Dysplasia in HIV Seropositive Women in a Urban South African Cancer Cohort (SACCC) Cynthia Firnhaber, MD, University of Witwatersrand, Johannesburg, South Africa
	11:35	Prevalence of Cervical Dysplasia in HIV-Positive Women in Jos, Nigeria Patricia Agaba, MD, AIDS Prevention Initiative in Nigeria, Jos University Teaching Hospital, Jos, Nigeria
	11:50	Infrared Coagulator (IRC) for Treatment of High-Grade Squamous Intraepithelial Neoplasia (HSIL) of the Anal Canal in HIV-Infected Individuals: A Pilot Study (AMC 032) Elizabeth Stier, MD, Boston Medical Center, Boston, MA, USA
	12:05	Interaction of HPV Pseudovirus with the Murine Female Genital Tract and Identification of Compounds That Can Potentiate or Inhibit In Vivo Infection Jeffrey Roberts, PhD, NCI-Frederick, Frederick, MD, USA
	12:20 PM–1:30 PM	Lunch
	1:30 PM–2:30 PM	Inflammation, Immunity and Malignancies Moderator: Elliott Kieff, MD, PhD
	1:30	P10: A Role for the Chemokine Receptor CXCR4 in the Homing of Kaposi’s Sarcoma–Associated Herpes Virus (KSHV)–Infected Cells Giovana Tosato, MD National Cancer Institute, NIH Bethesda, MD, USA
	2:00	P11: Liver and Inflammation Snorri S.Thorgeirsson, MD, PhD National Cancer Institute, NIH Bethesda, MD, USA
	2:30	Break
	2:50 PM–4:30 PM	Session 5: Emerging Themes in HIV/AIDS Malignancies Moderator: Catherine Godfrey, MD, and Mostafa Nokta, MD, PhD
	2:50	Conservation of Virally-Encoded MicroRNAs in the Kaposi's Sarcoma–Associated Herpesvirus (KSHV) in Primary Effusion Lymphoma Cell Lines and in Patients with Kaposi's Sarcoma or Multicentric Castleman's Disease Vickie Marshall, MS, NCI-Frederick, Frederick, MD, USA
	3:05	EBV Encoded Micro RNAs in Endemic and HIV Related Burkitt's Lymphoma William Harrington, MD, University of Miami, Miami, FL, USA
	3:20	Tumor Recognition and Cytolysis by the CD45RA/CD27–Effector Subset of Human VGVD2 T Cells Andrew Hebbeler, PhD, Institute of Human Virology, Baltimore, MD, USA
	3:35	Association of Cells with Natural Killer (NK) and NKT Immunophenotype with Incident Cancers in HIV-Infected Women Marek Nowicki, PhD, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
	3:50	Risk of Cancers During Interrupted Antiretroviral Therapy: Malignant Outcomes in the SMART Study Donald Abrams, MD, San Francisco General Hospital, University of San Francisco, CA, USA
	4:05	Detection and Typing of Mucosal and Cutaneous Human Papillomaviruses in AIDS-related Conjunctival Neoplasia in Uganda Franco Buonaguro, MD, National Cancer Institute Fond, Pascale, Naples, Italy
	4:20	Persistent Kaposi's Sarcoma in a Population Extensively Treated with Antiretroviral Agents and Chemotherapy: Characterizing the Predictors of Clinical Response Huong Nguyen, PhD, University of Washington, Seattle, WA
	4:35 PM–6:00 PM	Adjourn to Posters